Karaa 2023 — MMPOWER-3 Elamipretide Randomized Clinical Trial

Neurology·June 1, 2023

Amel Karaa, Bruce H. Cohen, Michio Hirano, MMPOWER-3 Investigators

Summary

MMPOWER-3 provided Class I evidence that elamipretide did not improve 6-minute walk distance or fatigue at 24 weeks compared with placebo in primary mitochondrial myopathy.

Study Details

Study Design

Phase 3 randomized double-blind placebo-controlled trial

Indication

Primary mitochondrial myopathy

Intervention

Subcutaneous elamipretide vs placebo

Species

Human

Sample Size

218 subjects

Risk of Bias Assessment

Negative phase 3 trial